GLP-1 drugs have transformed the treatment of type 2 diabetes and obesity. As governments and insurers debate whether and how to cover GLP-1 drugs, much of the discussion focuses on health spending. But obesity and diabetes also impose costs through the labour market. Using linked Danish register data, this column examines whether people are more likely to work after beginning treatment and spend less time away because of illness. The findings reveal that GLP-1 treatment reduces long-term sickness leave, as well as emergency department visits and cardiovascular medication use.



Source link